<a href="https://laohu8.com/S/ASND">Ascendis Pharma A/S</a> Presents Interim Results from COACH Trial on Achondroplasia Treatment
Ascendis Pharma A/S has released interim topline data from their Phase 2 COACH Trial, which is evaluating the combination treatment of TransCon CNP and TransCon hGH in children with achondroplasia. The Week 26 data revealed that in the TransCon CNP treatment-naïve cohort, the mean annualized growth velocity (AGV) was 9.14 cm/year, with an improvement in the mean ACH height Z-score of +0.53 over the 26 weeks. For the cohort previously treated with TransCon CNP, the mean AGV was 8.25 cm/year, with a +0.44 improvement in the mean ACH height Z-score over 26 weeks. The trial aims to assess the effect of the combination treatment on linear growth compared to TransCon CNP alone. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。